{"gene":"ARAP1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2002,"finding":"ARAP1 has PIP3-dependent Arf GAP activity and Rho GAP activity in vitro; it associates with the Golgi; Rho GAP activity mediates cell rounding and loss of stress fibers; Arf GAP activity mediates Golgi changes and filopodia formation via increased Cdc42 activity; both activities contribute to inhibiting cell spreading.","method":"In vitro GAP assays, overexpression with functional readouts (cell rounding, stress fibers, filopodia), Golgi localization by imaging","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic assays plus multiple cellular functional readouts in a foundational, highly-cited paper","pmids":["11804590"],"is_preprint":false},{"year":2003,"finding":"ARAP1 (493-aa isoform identified by yeast two-hybrid) binds the C-terminal region of the angiotensin II type 1A receptor (AT1A) and promotes recycling of internalized AT1A to the plasma membrane in HEK-293 cells, co-localizing with recycled AT1A at the membrane 45 min after Ang II treatment.","method":"Yeast two-hybrid, co-immunoprecipitation, immunocytochemistry, functional Ca2+ release assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — reciprocal Co-IP plus co-localization and functional assay, single lab","pmids":["14559250"],"is_preprint":false},{"year":2008,"finding":"ARAP1 is recruited transiently to Rab5-positive, EEA1-negative early endocytic puncta containing EGFR upon EGF stimulation; knockdown of ARAP1 accelerates EGF association with EEA1 endosomes and EGFR degradation, and reduces duration of ERK and JNK phosphorylation, indicating ARAP1 controls an early endocytic checkpoint to delay EGFR signal attenuation.","method":"siRNA knockdown, live/fixed imaging with Rab5/EEA1/rabaptin-5 markers, EGFR degradation assay, ERK/JNK phosphorylation time course","journal":"Traffic (Copenhagen, Denmark)","confidence":"High","confidence_rationale":"Tier 2 — clean KD with defined cellular phenotype plus multiple orthogonal readouts, replicated by independent lab (PMID 18764928)","pmids":["18939958"],"is_preprint":false},{"year":2008,"finding":"ARAP1 localizes to Golgi and endosomal compartments, enriched in internal membranes of multivesicular bodies; its distribution is controlled by phosphorylation and by binding to 3- and 4-phosphorylated phosphoinositides through its PH domains; ARAP1 knockdown causes EGFR accumulation in sorting/late endosomes and inhibits EGFR degradation with prolonged downstream signaling.","method":"Subcellular fractionation, immunofluorescence, siRNA knockdown, EGFR trafficking/degradation assay, phosphorylation analysis","journal":"Traffic (Copenhagen, Denmark)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, independent replication of ARAP1 endosomal function (consistent with PMID 18939958)","pmids":["18764928"],"is_preprint":false},{"year":2009,"finding":"The first PH domain (PH1) of ARAP1 specifically binds PtdIns(3,4,5)P3 with ~1.6 µM affinity; this binding allosterically stimulates Arf GAP catalytic activity without mediating membrane recruitment; PtdIns(3,4,5)P3 binding to PH1 is required for ARAP1 function as a regulator of EGFR endocytic trafficking in cells.","method":"Lipid-binding assays (in vitro), in vitro GAP activity assay with PH domain mutants, membrane recruitment assay in cells, EGFR trafficking assay with PH mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis plus cellular functional validation","pmids":["19666464"],"is_preprint":false},{"year":2010,"finding":"PTK6 (Brk) directly phosphorylates ARAP1 at Tyr231; this phosphorylation is EGF/EGFR-dependent and requires the SH2 domain (Arg105) of PTK6; phosphorylated ARAP1 inhibits EGFR down-regulation, whereas the Y231F mutant of ARAP1 does not, linking PTK6-mediated phosphorylation of ARAP1 to sustained EGFR signaling in breast cancer cells.","method":"Co-immunoprecipitation, MALDI-TOF mass spectrometry, in vitro/cell-based phosphorylation assay, site-directed mutagenesis (Y231F), EGFR degradation assay, PTK6 siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — phosphorylation identified by mass spec, confirmed by mutagenesis, with functional rescue assay","pmids":["20554524"],"is_preprint":false},{"year":2011,"finding":"ARAP1 associates with CIN85 via its PXPXXRX motif (Arg86/Arg90) interacting with CIN85 SH3 domains; this interaction is required for ARAP1-dependent routing of EGFR away from the EEA1-positive early endosome; ARAP1 overexpression reduces Cbl-mediated EGFR ubiquitination and slows Cbl-dependent EGFR degradation, and a CIN85-binding-deficient ARAP1 mutant fails to rescue EGFR trafficking.","method":"Co-immunoprecipitation, mutagenesis, siRNA knockdown (ARAP1 and CIN85), EGFR ubiquitination assay, EGFR degradation assay","journal":"Biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, mutagenesis, and multiple functional assays in one study","pmids":["21275903"],"is_preprint":false},{"year":2012,"finding":"ARAP1 is recruited to circular dorsal ruffles (CDRs) upon growth factor stimulation and increases CDR ring size in an Arf GAP activity-dependent manner; dominant-negative Arf1 and Arf5 expand CDR size, placing Arf1 and Arf5 downstream of ARAP1 in CDR ring size control.","method":"Overexpression/knockdown with live imaging and phalloidin staining, dominant-negative Arf constructs, Arf GAP-dead ARAP1 mutants","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (dominant-negative Arfs) plus gain/loss-of-function with specific morphological readout","pmids":["22573888"],"is_preprint":false},{"year":2013,"finding":"Arap1-deficient mice show reduced vascular sensitivity to angiotensin II (demonstrated in isolated perfused kidney), accelerated sepsis-induced hypotension, and increased plasma renin concentration, consistent with ARAP1 promoting AT1 receptor surface expression in vascular smooth muscle/mesangial cells in vivo.","method":"Arap1 knockout mouse, isolated perfused kidney vascular resistance assay, telemetric blood pressure, LPS endotoxemia model","journal":"Critical care (London, England)","confidence":"High","confidence_rationale":"Tier 2 — knockout mouse with defined physiological phenotype plus in vitro vascular assay","pmids":["23844607"],"is_preprint":false},{"year":2008,"finding":"ARAP1 interacts with the intracellular part of TRAIL death receptor DR4 (identified by yeast two-hybrid); ARAP1 co-precipitates with DR4 and co-localizes with it in the ER/Golgi, plasma membrane, and early endosomes; ARAP1 knockdown significantly reduces DR4 cell-surface localization in tumor cell lines and slows TRAIL-induced death.","method":"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown, flow cytometry for surface DR4, cell death assay","journal":"Apoptosis : an international journal on programmed cell death","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple methods in single lab; functional consequence of knockdown demonstrated","pmids":["18165900"],"is_preprint":false},{"year":2018,"finding":"In osteoclasts, ARAP1 is part of a podosome/sealing zone complex where its RhoGAP domain regulates actin dynamics; at endosomes, ARAP1 interacts with AP-3 adaptor complexes and its Arf-GAP domain regulates Arf1-dependent AP-3 membrane binding, controlling lysosomal membrane protein transport to ruffled borders; ARAP1 or AP-3 depletion reduces osteoclast bone-digesting capacity in vitro, and AP-3δ-deficient mocha mice develop osteoporosis.","method":"Co-immunoprecipitation, domain-specific mutants, siRNA knockdown, bone resorption assay, mouse model (mocha)","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, domain mutants, multiple functional assays, and in vivo mouse model","pmids":["30240610"],"is_preprint":false},{"year":2018,"finding":"Crystal structure and biochemical analysis revealed that the CIN85 SH3B domain binds the ARAP1 PXPXXRX(except P)XXR/H/K motif with high affinity and specificity; the β2-β3 loops of CIN85 SH3 domains and H87ARAP1/E132CIN85 interaction confer binding specificity; ARAP1 competes with Cbl for CIN85 binding, providing a structural basis for ARAP1-mediated attenuation of EGFR internalization.","method":"Crystal structure determination, ITC, analytical gel-filtration chromatography, mutagenesis, domain-swapping","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus ITC quantification plus mutagenesis validation","pmids":["29589748"],"is_preprint":false},{"year":2017,"finding":"Arap1 knockout mice develop photoreceptor degeneration starting at 4 weeks; Arap1 is expressed in Müller glia (not photoreceptors), implicating a non-cell-autonomous role of ARAP1 in photoreceptor survival via Müller glia.","method":"Knockout mouse, OCT imaging, fundus photography, immunohistochemistry, electroretinography","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 — knockout mouse with well-defined retinal phenotype, though mechanism unresolved","pmids":["28324111"],"is_preprint":false},{"year":2022,"finding":"Conditional knockout of Arap1 in RPE (using Vmd2-Cre) but not in Müller glia (Glast-Cre) recapitulates the photoreceptor degeneration phenotype; Arap1-/- RPE shows a clear phagocytic defect in vivo; mass spectrometry of ARAP1 co-IP identified candidate binding partners involved in phagocytosis, cytoskeletal organization, and intracellular trafficking.","method":"Conditional knockout mouse (cell-type-specific Cre lines), outer-segment phagocytosis quantification in vivo, co-immunoprecipitation mass spectrometry","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific knockouts precisely localize function to RPE, phagocytosis directly quantified in vivo","pmids":["35758026"],"is_preprint":false},{"year":2023,"finding":"ARAP1 overexpression significantly inhibits migration and invasion of lung adenocarcinoma cells in vitro and in vivo; an Arf-GAP-dead mutant does not rescue, whereas RhoGAP activity is responsible for suppressing stress fiber formation and thereby metastasis.","method":"Overexpression with RhoGAP-dead mutant controls, stress fiber imaging, Transwell migration/invasion assay, in vivo xenograft","journal":"Discover oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 — domain-specific mutant analysis plus in vivo validation, single lab","pmids":["38008882"],"is_preprint":false},{"year":2025,"finding":"ARAP1 modulates RhoA activity at cell protrusions via its RA domain, which binds Rap1 and Rac1; ARAP1-deficient lymphocytes show enhanced chemokine-directed migration with increased RhoA activation and F-actin polymerization; ARAP1 overexpression inhibits migration in a RhoGAP-domain-dependent manner; the RA domain binding of Rap1/Rac1 is required for ARAP1-mediated RhoA inhibition.","method":"ARAP1 knockout/overexpression, Rho biosensor imaging, F-actin measurement, RA-domain mutants, Rap1/Rac1 binding assay, chemotaxis assay","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including live biosensor imaging, domain-specific mutants, and defined cellular phenotype","pmids":["41488654"],"is_preprint":false},{"year":2014,"finding":"The T2D-risk allele (C) of rs11603334, near an ARAP1 promoter, shows ~2-fold higher transcriptional activity in reporter assays and reduced binding of transcriptional regulators PAX6 and PAX4 in EMSA; the C allele is associated with increased ARAP1 mRNA in human pancreatic islet samples, suggesting PAX6/PAX4-mediated repression normally limits ARAP1 expression in beta cells.","method":"Luciferase reporter assay in pancreatic beta cell lines, EMSA, allele-specific mRNA quantification in human islets","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay plus EMSA plus human islet allele-specific expression, single lab","pmids":["24439111"],"is_preprint":false},{"year":2020,"finding":"ARAP1 maintains persistent EGFR activation in high-glucose-treated HK-2 cells by reducing EGFR ubiquitination through competing with Cbl for CIN85 binding; lncRNA ARAP1-AS2 directly interacts with ARAP1 protein (RNA pulldown), promoting this mechanism to activate TGF-β/Smad3 signaling and fibrosis.","method":"RNA pulldown, co-immunoprecipitation, ubiquitination assay, dual-immunofluorescence, EGFR signaling assay, siRNA/overexpression","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — mechanistic dissection of ARAP1/CIN85/Cbl competition confirmed by ubiquitination and Co-IP, single lab","pmids":["32969198"],"is_preprint":false},{"year":2025,"finding":"In Hep3B hepatocellular carcinoma cells, ARAP1 localizes to CDRs and mitochondria (not observed in control HCC lines); ARAP1 KO reduces CDR size, disrupts lamellipodia architecture, attenuates macropinocytic nutrient uptake, and reduces cell growth and invasive potential; ARAP1 is actively degraded via proteasome in Hep3B cells, explaining its lower absolute level despite pro-CDR function.","method":"ARAP1 CRISPR KO, confocal microscopy, high-resolution SEM, proteasome inhibitor (MG132), macropinocytosis assay, cell proliferation and Transwell assays","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2 — KO plus pharmacological tools plus multiple imaging modalities, single lab","pmids":["39934854"],"is_preprint":false}],"current_model":"ARAP1 is a PIP3-dependent dual GTPase-activating protein (Arf GAP and Rho GAP) that integrates phosphoinositide, Arf, and Rho signaling: its PH1 domain binds PIP3 to allosterically activate Arf GAP catalytic activity (targeting Arf1/Arf5), while its RhoGAP domain suppresses RhoA/Rho-driven actin stress fibers; at the endosomal level, ARAP1 associates with CIN85 (via a defined PXPXXR motif characterized structurally) to delay EGFR routing to EEA1-positive early endosomes and compete with Cbl for CIN85 binding, thereby reducing EGFR ubiquitination and slowing receptor degradation; PTK6 phosphorylates ARAP1-Tyr231 in an EGF-dependent manner to reinforce this pro-EGFR effect; ARAP1 also promotes AT1 receptor recycling to the plasma membrane and DR4 surface presentation, regulates CDR ring size through Arf1/5, and in the retina, ARAP1 expression in the RPE is required for outer-segment phagocytosis and photoreceptor survival; in lymphocytes, its RA domain binds Rap1/Rac1 at protrusions to spatially restrict RhoA activity and fine-tune F-actin polymerization and migration."},"narrative":{"teleology":[{"year":2002,"claim":"The foundational enzymatic activities of ARAP1 were established: PIP3-dependent Arf GAP and Rho GAP activities that respectively regulate Golgi morphology/filopodia and stress fiber disassembly, defining ARAP1 as a dual-specificity GAP linking phosphoinositide signaling to cytoskeletal and membrane dynamics.","evidence":"In vitro GAP assays and overexpression phenotypes (cell rounding, filopodia, Golgi changes) in cultured cells","pmids":["11804590"],"confidence":"High","gaps":["Endogenous substrates (which Arf and Rho family members) not fully resolved in vivo","Membrane targeting mechanism not yet defined","Physiological contexts beyond overexpression not tested"]},{"year":2003,"claim":"ARAP1 was linked to GPCR recycling by demonstrating that it binds the AT1A receptor cytoplasmic tail and promotes receptor recycling to the plasma membrane, extending its functional scope beyond cytoskeletal regulation.","evidence":"Yeast two-hybrid, co-IP, co-localization, and calcium release assay in HEK-293 cells","pmids":["14559250"],"confidence":"Medium","gaps":["Shorter 493-aa isoform used; relevance to full-length protein unclear","No loss-of-function validation of receptor recycling at this stage","Mechanism linking Arf GAP activity to receptor recycling not dissected"]},{"year":2008,"claim":"Two independent studies converged to establish ARAP1 as a gatekeeper of early endosomal trafficking: ARAP1 is recruited to Rab5-positive/EEA1-negative compartments upon EGF stimulation, and its depletion accelerates EGFR transit to EEA1 endosomes and modulates receptor degradation kinetics and downstream MAPK signaling duration.","evidence":"siRNA knockdown with live/fixed imaging, EGFR degradation assays, ERK/JNK phosphorylation time courses, subcellular fractionation (two independent labs)","pmids":["18939958","18764928"],"confidence":"High","gaps":["Mechanism of ARAP1 recruitment to pre-EEA1 compartments undefined","Which GAP activity (Arf or Rho) mediates the endosomal checkpoint not resolved","Role of PH domain–PIP3 interaction in endosomal function not yet tested"]},{"year":2008,"claim":"ARAP1 was shown to interact with death receptor DR4 and promote its surface presentation, linking ARAP1 trafficking function to TRAIL-mediated apoptosis.","evidence":"Yeast two-hybrid, co-IP, co-localization, siRNA knockdown with surface DR4 quantification and cell death assay in tumor cell lines","pmids":["18165900"],"confidence":"Medium","gaps":["No in vivo validation","Mechanism by which ARAP1 promotes DR4 surface localization not defined","Whether Arf GAP or Rho GAP activity is involved not tested"]},{"year":2009,"claim":"The allosteric activation mechanism was defined: PH1-domain binding of PtdIns(3,4,5)P3 (~1.6 µM Kd) stimulates Arf GAP catalytic activity without being required for membrane recruitment, establishing the molecular logic by which PI3K signaling controls ARAP1 enzymatic output.","evidence":"In vitro lipid-binding and GAP assays with PH domain mutants, cellular EGFR trafficking rescue experiments","pmids":["19666464"],"confidence":"High","gaps":["Structural basis of allosteric activation not determined","How PH1 mutants affect Rho GAP activity not tested","Relative contributions of PIP3-dependent versus PIP3-independent activity in vivo unknown"]},{"year":2010,"claim":"PTK6-mediated phosphorylation of ARAP1-Tyr231 was identified as an EGF-dependent post-translational switch that reinforces ARAP1's ability to inhibit EGFR degradation, connecting receptor tyrosine kinase signaling to ARAP1 regulation.","evidence":"Mass spectrometry identification of pY231, mutagenesis (Y231F), PTK6 knockdown, EGFR degradation assays in breast cancer cells","pmids":["20554524"],"confidence":"High","gaps":["Downstream consequence of pY231 on GAP activity or protein interactions not resolved","Whether other kinases phosphorylate Y231 not tested","Relevance outside breast cancer cells not established"]},{"year":2011,"claim":"The molecular mechanism of ARAP1's endosomal checkpoint was clarified: ARAP1 binds CIN85 SH3 domains via a PXPXXR motif, competes with Cbl for CIN85 binding, reduces EGFR ubiquitination, and a CIN85-binding-deficient mutant fails to regulate EGFR trafficking.","evidence":"Co-IP, mutagenesis (Arg86/Arg90), siRNA of ARAP1 and CIN85, EGFR ubiquitination and degradation assays","pmids":["21275903"],"confidence":"High","gaps":["Stoichiometry of ARAP1–CIN85–Cbl competition in endogenous complexes unknown","Whether Arf GAP activity is required in addition to CIN85 binding for the checkpoint not tested"]},{"year":2012,"claim":"ARAP1 was placed upstream of Arf1 and Arf5 in circular dorsal ruffle morphogenesis: ARAP1 increases CDR ring size in an Arf GAP-dependent manner, and dominant-negative Arf1/5 phenocopy ARAP1 overexpression.","evidence":"Overexpression and knockdown with live imaging, Arf GAP-dead mutants, dominant-negative Arf constructs","pmids":["22573888"],"confidence":"High","gaps":["Whether CDR size regulation affects macropinocytosis not addressed at this stage","Mechanism linking Arf inactivation to CDR expansion not defined"]},{"year":2013,"claim":"In vivo physiological relevance was demonstrated: Arap1-knockout mice show reduced vascular sensitivity to angiotensin II and accelerated sepsis-induced hypotension, validating ARAP1's role in AT1 receptor recycling and vascular tone regulation.","evidence":"Arap1 knockout mouse, isolated perfused kidney, telemetric blood pressure, LPS endotoxemia model","pmids":["23844607"],"confidence":"High","gaps":["Cell-type-specific contribution (smooth muscle vs. endothelium) not resolved","Whether the vascular phenotype involves Arf GAP, Rho GAP, or both activities not determined"]},{"year":2014,"claim":"A type 2 diabetes risk allele (rs11603334 C) was linked to increased ARAP1 transcription in pancreatic islets via reduced PAX6/PAX4 repressor binding, implicating ARAP1 expression levels in beta-cell biology.","evidence":"Luciferase reporter assay, EMSA, allele-specific mRNA quantification in human islets","pmids":["24439111"],"confidence":"Medium","gaps":["Functional consequence of increased ARAP1 in beta cells not established","No beta-cell-specific knockout or gain-of-function study performed","Causality between ARAP1 levels and diabetes risk not demonstrated"]},{"year":2017,"claim":"Arap1 knockout mice develop photoreceptor degeneration from 4 weeks of age, with ARAP1 expressed in Müller glia, initially suggesting a non-cell-autonomous support mechanism for photoreceptor survival.","evidence":"Knockout mouse with OCT, fundus imaging, immunohistochemistry, ERG","pmids":["28324111"],"confidence":"Medium","gaps":["Cell-type responsible for the phenotype not definitively assigned","Mechanism of photoreceptor degeneration unknown","Müller glia attribution later revised by conditional knockout data"]},{"year":2018,"claim":"Two studies expanded ARAP1's functional scope: structurally, the CIN85 SH3B–ARAP1 PXPXXR interaction was resolved by crystallography, explaining specificity and competition with Cbl; functionally, ARAP1 was shown to regulate osteoclast bone resorption via RhoGAP-dependent podosome dynamics and ArfGAP-dependent AP-3-mediated lysosomal transport to ruffled borders.","evidence":"Crystal structure, ITC, mutagenesis for CIN85 binding; co-IP, domain mutants, siRNA, bone resorption assay, mocha mouse model for osteoclast function","pmids":["29589748","30240610"],"confidence":"High","gaps":["How ARAP1-AP-3 interaction is regulated at endosomes not defined","Whether CIN85 structural insights apply to osteoclast trafficking not tested"]},{"year":2020,"claim":"The ARAP1–CIN85–Cbl competition mechanism was validated in diabetic nephropathy models, where lncRNA ARAP1-AS2 binds ARAP1 protein to sustain EGFR activation and drive TGF-β/Smad3 fibrotic signaling under high glucose.","evidence":"RNA pulldown, co-IP, ubiquitination assay, EGFR signaling in HK-2 cells under high glucose","pmids":["32969198"],"confidence":"Medium","gaps":["How ARAP1-AS2 binding modulates ARAP1 protein function mechanistically is unclear","In vivo relevance in diabetic kidney not shown","Generalizability beyond HK-2 cell line not tested"]},{"year":2022,"claim":"Cell-type-specific conditional knockouts definitively assigned the retinal phenotype to RPE (not Müller glia): RPE-specific Arap1 deletion recapitulates photoreceptor degeneration with a clear phagocytic defect, revising the earlier Müller glia hypothesis.","evidence":"Conditional knockout (Vmd2-Cre for RPE, Glast-Cre for Müller glia), in vivo phagocytosis quantification, co-IP mass spectrometry","pmids":["35758026"],"confidence":"High","gaps":["Specific phagocytic step requiring ARAP1 (recognition, engulfment, digestion) not defined","Which GAP activity mediates RPE phagocytosis not tested","Candidate partners from mass spectrometry not validated"]},{"year":2023,"claim":"ARAP1's RhoGAP activity was shown to suppress lung adenocarcinoma migration and invasion by eliminating stress fibers, with an Arf-GAP-dead mutant retaining anti-metastatic function, demonstrating domain-specific contributions to cancer cell motility.","evidence":"Overexpression with domain-specific mutants, Transwell assays, in vivo xenograft","pmids":["38008882"],"confidence":"Medium","gaps":["Endogenous ARAP1 expression/loss-of-function in lung adenocarcinoma not tested","Whether RhoGAP activity alone suffices in other cancer contexts unknown","Downstream RhoA effectors mediating anti-metastatic effect not identified"]},{"year":2025,"claim":"ARAP1's RA domain was shown to bind Rap1 and Rac1 at lymphocyte protrusions, spatially restricting RhoA activity; ARAP1-deficient lymphocytes exhibit enhanced migration with increased RhoA and F-actin, establishing a Rap1/Rac1→ARAP1→RhoA signaling axis in immune cell motility.","evidence":"Knockout and overexpression, Rho biosensor live imaging, RA-domain mutants, chemotaxis assay in lymphocytes","pmids":["41488654"],"confidence":"High","gaps":["How RA domain binding activates RhoGAP catalysis mechanistically unknown","In vivo immune phenotype of ARAP1-deficient lymphocytes not characterized","Whether Rap1 and Rac1 act redundantly or sequentially not resolved"]},{"year":2025,"claim":"In hepatocellular carcinoma cells, ARAP1 was shown to localize to CDRs and mitochondria, with ARAP1 knockout reducing CDR size, macropinocytic nutrient uptake, and cell growth; ARAP1 is actively degraded via the proteasome in these cells.","evidence":"CRISPR KO, confocal and SEM imaging, macropinocytosis assay, MG132 treatment in Hep3B cells","pmids":["39934854"],"confidence":"Medium","gaps":["Mitochondrial localization not validated by independent methods or in other cell types","Whether macropinocytosis effect is Arf GAP-dependent not tested","Mechanism of proteasomal targeting not defined"]},{"year":null,"claim":"Key unresolved questions include the structural basis for PIP3-mediated allosteric activation of ARAP1's Arf GAP domain, the specific phagocytic substep requiring ARAP1 in RPE, and how the RA domain mechanistically couples Rap1/Rac1 binding to RhoGAP catalytic activation.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length ARAP1 structure available","No reconstituted phagocytosis assay with defined ARAP1 mutants in RPE","Inter-domain allosteric communication not characterized biochemically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,7,15]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,4]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,7,10]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,3,9]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[2,3,10]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,9]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[7,10,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,5,15]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[2,3,6,11]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9]}],"complexes":[],"partners":["CIN85","EGFR","AGTR1","TNFRSF10A","PTK6","AP3D1","RAP1A","RAC1"],"other_free_text":[]},"mechanistic_narrative":"ARAP1 is a phosphoinositide-regulated dual GTPase-activating protein that coordinates Arf and Rho GTPase signaling to control endosomal trafficking, actin cytoskeletal remodeling, and receptor fate decisions. Its PH1 domain binds PtdIns(3,4,5)P3 with micromolar affinity to allosterically activate Arf GAP catalytic activity targeting Arf1/Arf5, while its RhoGAP domain inactivates RhoA to suppress stress fibers and regulate cell migration; an RA domain binds Rap1/Rac1 at cell protrusions to spatially restrict RhoA activity [PMID:11804590, PMID:19666464, PMID:41488654]. ARAP1 controls an early endocytic checkpoint for EGFR by associating with CIN85 via a structurally characterized PXPXXR motif, competing with Cbl for CIN85 binding to reduce EGFR ubiquitination and delay receptor degradation, a process reinforced by PTK6-mediated phosphorylation of ARAP1-Tyr231 [PMID:18939958, PMID:21275903, PMID:29589748, PMID:20554524]. In the retina, ARAP1 expression in the retinal pigment epithelium is required for outer-segment phagocytosis and photoreceptor survival, as conditional RPE-specific knockout recapitulates the photoreceptor degeneration seen in global knockouts [PMID:35758026, PMID:28324111]."},"prefetch_data":{"uniprot":{"accession":"Q96P48","full_name":"Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1","aliases":["Centaurin-delta-2","Cnt-d2"],"length_aa":1450,"mass_kda":162.2,"function":"Phosphatidylinositol 3,4,5-trisphosphate-dependent GTPase-activating protein that modulates actin cytoskeleton remodeling by regulating ARF and RHO family members (PubMed:11804590, PubMed:19666464). Activated by phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) binding and, to a lesser extent, by phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) binding (PubMed:11804590). Has a preference for ARF1 and ARF5 (PubMed:11804590, PubMed:19666464). Positively regulates the ring size of circular dorsal ruffles and promotes macropinocytosis (PubMed:22573888). Acts as a bridging factor in osteoclasts to control actin and membrane dynamics (By similarity). Regulates the condensing of osteoclast podosomes into sealing zones which segregate the bone-facing membrane from other membrane domains and are required for osteoclast resorption activity (By similarity). Also regulates recruitment of the AP-3 complex to endosomal membranes and trafficking of lysosomal membrane proteins to the ruffled membrane border of osteoclasts to modulate bone resorption (By similarity). Regulates the endocytic trafficking of EGFR (PubMed:18764928, PubMed:18939958, PubMed:21275903). Regulates the incorporation of CD63 and CD9 into multivesicular bodies (PubMed:38682696). Required in the retinal pigment epithelium (RPE) for photoreceptor survival due to its role in promoting RPE phagocytosis (By similarity)","subcellular_location":"Cytoplasm; Golgi apparatus, trans-Golgi network; Golgi apparatus, Golgi stack; Cell membrane; Endosome, multivesicular body; Cell projection, ruffle; Cell projection, podosome; Early endosome","url":"https://www.uniprot.org/uniprotkb/Q96P48/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARAP1","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"DNAJB6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ARAP1","total_profiled":1310},"omim":[{"mim_id":"606647","title":"ARF-GAP, RHO-GAP, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 3; ARAP3","url":"https://www.omim.org/entry/606647"},{"mim_id":"606646","title":"ARF-GAP, RHO-GAP, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 1; ARAP1","url":"https://www.omim.org/entry/606646"},{"mim_id":"606645","title":"ARF-GAP, RHO-GAP, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 2; ARAP2","url":"https://www.omim.org/entry/606645"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARAP1"},"hgnc":{"alias_symbol":[],"prev_symbol":["CENTD2"]},"alphafold":{"accession":"Q96P48","domains":[{"cath_id":"1.10.150.50","chopping":"12-67","consensus_level":"high","plddt":86.9493,"start":12,"end":67},{"cath_id":"2.30.29.30","chopping":"332-425","consensus_level":"medium","plddt":87.3484,"start":332,"end":425},{"cath_id":"2.30.29.30","chopping":"445-533","consensus_level":"medium","plddt":88.1179,"start":445,"end":533},{"cath_id":"1.10.220.150","chopping":"535-720","consensus_level":"medium","plddt":92.5427,"start":535,"end":720},{"cath_id":"2.30.29.30","chopping":"740-850","consensus_level":"medium","plddt":89.6135,"start":740,"end":850},{"cath_id":"2.30.29.30","chopping":"858-955","consensus_level":"medium","plddt":83.2815,"start":858,"end":955},{"cath_id":"1.10.555.10","chopping":"961-1165","consensus_level":"high","plddt":88.0433,"start":961,"end":1165},{"cath_id":"2.30.29.30","chopping":"1175-1290_1297-1318_1334-1397","consensus_level":"medium","plddt":84.7263,"start":1175,"end":1397}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96P48","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96P48-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96P48-F1-predicted_aligned_error_v6.png","plddt_mean":74.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARAP1","jax_strain_url":"https://www.jax.org/strain/search?query=ARAP1"},"sequence":{"accession":"Q96P48","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96P48.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96P48/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96P48"}},"corpus_meta":[{"pmid":"11804590","id":"PMC_11804590","title":"ARAP1: a point of convergence for Arf and Rho signaling.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11804590","citation_count":155,"is_preprint":false},{"pmid":"24439111","id":"PMC_24439111","title":"A common functional regulatory variant at a type 2 diabetes locus upregulates ARAP1 expression in the pancreatic beta cell.","date":"2014","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24439111","citation_count":65,"is_preprint":false},{"pmid":"14559250","id":"PMC_14559250","title":"Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14559250","citation_count":53,"is_preprint":false},{"pmid":"23844607","id":"PMC_23844607","title":"The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension.","date":"2013","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23844607","citation_count":46,"is_preprint":false},{"pmid":"18939958","id":"PMC_18939958","title":"ARAP1 regulates endocytosis of EGFR.","date":"2008","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/18939958","citation_count":42,"is_preprint":false},{"pmid":"16801480","id":"PMC_16801480","title":"Development of hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1 gene in the kidney.","date":"2006","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/16801480","citation_count":41,"is_preprint":false},{"pmid":"31173500","id":"PMC_31173500","title":"YY1-Induced Upregulation of Long Noncoding RNA ARAP1-AS1 Promotes Cell Migration and Invasion in Colorectal Cancer Through the Wnt/β-Catenin Signaling Pathway.","date":"2019","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31173500","citation_count":41,"is_preprint":false},{"pmid":"18764928","id":"PMC_18764928","title":"ARAP1 regulates EGF receptor trafficking and signalling.","date":"2008","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/18764928","citation_count":36,"is_preprint":false},{"pmid":"21267535","id":"PMC_21267535","title":"Type 2 diabetes risk allele near CENTD2 is associated with decreased glucose-stimulated insulin release.","date":"2011","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/21267535","citation_count":36,"is_preprint":false},{"pmid":"31953923","id":"PMC_31953923","title":"Long non-coding RNA ARAP1-AS1 promotes tumorigenesis and metastasis through facilitating proto-oncogene c-Myc translation via dissociating PSF/PTB dimer in cervical cancer.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31953923","citation_count":33,"is_preprint":false},{"pmid":"22573888","id":"PMC_22573888","title":"ARAP1 regulates the ring size of circular dorsal ruffles through Arf1 and Arf5.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22573888","citation_count":32,"is_preprint":false},{"pmid":"20554524","id":"PMC_20554524","title":"PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20554524","citation_count":30,"is_preprint":false},{"pmid":"19666464","id":"PMC_19666464","title":"A PH domain in the Arf GTPase-activating protein (GAP) ARAP1 binds phosphatidylinositol 3,4,5-trisphosphate and regulates Arf GAP activity independently of recruitment to the plasma membranes.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19666464","citation_count":30,"is_preprint":false},{"pmid":"31975379","id":"PMC_31975379","title":"The effect of lncRNA-ARAP1-AS2/ARAP1 on high glucose-induced cytoskeleton rearrangement and epithelial-mesenchymal transition in human renal tubular epithelial cells.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31975379","citation_count":29,"is_preprint":false},{"pmid":"32110804","id":"PMC_32110804","title":"Long non-coding RNA ARAP1-AS1 accelerates cell proliferation and migration in breast cancer through miR-2110/HDAC2/PLIN1 axis.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32110804","citation_count":29,"is_preprint":false},{"pmid":"30404578","id":"PMC_30404578","title":"Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30404578","citation_count":26,"is_preprint":false},{"pmid":"31849504","id":"PMC_31849504","title":"Ursolic Acid Treatment Alleviates Diabetic Kidney Injury By Regulating The ARAP1/AT1R Signaling Pathway.","date":"2019","source":"Diabetes, metabolic syndrome and obesity : targets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31849504","citation_count":24,"is_preprint":false},{"pmid":"36874012","id":"PMC_36874012","title":"YY1-induced upregulation of LncRNA-ARAP1-AS2 and ARAP1 promotes diabetic kidney fibrosis via aberrant glycolysis associated with EGFR/PKM2/HIF-1α pathway.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36874012","citation_count":24,"is_preprint":false},{"pmid":"18165900","id":"PMC_18165900","title":"Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane.","date":"2008","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/18165900","citation_count":23,"is_preprint":false},{"pmid":"32969198","id":"PMC_32969198","title":"LncRNA ARAP1-AS2 promotes high glucose-induced human proximal tubular cell injury via persistent transactivation of the EGFR by interacting with ARAP1.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32969198","citation_count":21,"is_preprint":false},{"pmid":"21275903","id":"PMC_21275903","title":"ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking.","date":"2011","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/21275903","citation_count":19,"is_preprint":false},{"pmid":"32985327","id":"PMC_32985327","title":"Long non-coding RNA ARAP1-AS1 promotes the proliferation and migration in cervical cancer through epigenetic regulation of DUSP5.","date":"2020","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32985327","citation_count":19,"is_preprint":false},{"pmid":"33965958","id":"PMC_33965958","title":"Long Non-Coding RNA ARAP1-AS1 Facilitates the Progression of Cervical Cancer by Regulating miR-149-3p and POU2F2.","date":"2021","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33965958","citation_count":18,"is_preprint":false},{"pmid":"22357923","id":"PMC_22357923","title":"Angiotensin AT1 receptor-associated protein Arap1 in the kidney vasculature is suppressed by angiotensin II.","date":"2012","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22357923","citation_count":17,"is_preprint":false},{"pmid":"34516333","id":"PMC_34516333","title":"Long non-coding RNA ARAP1-AS1 contributes to cell proliferation and migration in clear cell renal cell carcinoma via the miR-361-3p/placental growth factor axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34516333","citation_count":13,"is_preprint":false},{"pmid":"25749274","id":"PMC_25749274","title":"Joint effect of CENTD2 and KCNQ1 polymorphisms on the risk of type 2 diabetes mellitus among Chinese Han population.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25749274","citation_count":12,"is_preprint":false},{"pmid":"30240610","id":"PMC_30240610","title":"ARAP1 Bridges Actin Dynamics and AP-3-Dependent Membrane Traffic in Bone-Digesting Osteoclasts.","date":"2018","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30240610","citation_count":12,"is_preprint":false},{"pmid":"33447422","id":"PMC_33447422","title":"Low expression of long non-coding RNA ARAP1-AS1 can inhibit lung cancer proliferation by inducing G0/G1 cell cycle organization.","date":"2020","source":"Journal of thoracic disease","url":"https://pubmed.ncbi.nlm.nih.gov/33447422","citation_count":11,"is_preprint":false},{"pmid":"35556220","id":"PMC_35556220","title":"LncRNA ARAP1-AS1 Promotes Bladder Cancer Development by Regulating the miR-3918/KIF20A Axis.","date":"2022","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35556220","citation_count":10,"is_preprint":false},{"pmid":"29589748","id":"PMC_29589748","title":"Biochemical and Structural Studies of the Interaction between ARAP1 and CIN85.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29589748","citation_count":9,"is_preprint":false},{"pmid":"34149172","id":"PMC_34149172","title":"LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian cancer cells through sponging miR-4735-3p to enhance PLAGL2 expression.","date":"2021","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/34149172","citation_count":9,"is_preprint":false},{"pmid":"28324111","id":"PMC_28324111","title":"Arap1 Deficiency Causes Photoreceptor Degeneration in Mice.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28324111","citation_count":8,"is_preprint":false},{"pmid":"35163144","id":"PMC_35163144","title":"Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163144","citation_count":6,"is_preprint":false},{"pmid":"36730555","id":"PMC_36730555","title":"LncRNA ARAP1-AS1 targets miR-516b-5p/PDE5A axis to facilitate the progression of thyroid cancer.","date":"2022","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/36730555","citation_count":6,"is_preprint":false},{"pmid":"35758026","id":"PMC_35758026","title":"Arap1 loss causes retinal pigment epithelium phagocytic dysfunction and subsequent photoreceptor death.","date":"2022","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/35758026","citation_count":5,"is_preprint":false},{"pmid":"38008882","id":"PMC_38008882","title":"ARAP1 negatively regulates stress fibers formation and metastasis in lung adenocarcinoma via controlling Rho signaling.","date":"2023","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38008882","citation_count":4,"is_preprint":false},{"pmid":"37545214","id":"PMC_37545214","title":"LncRNA ARAP1-AS1 contributes to lung adenocarcinoma development by targeting miR-8068 to upregulate CEACAM5.","date":"2023","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/37545214","citation_count":4,"is_preprint":false},{"pmid":"35185295","id":"PMC_35185295","title":"Correction to: LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian cancer cells through sponging miR-4735-3p to enhance PLAGL2 expression.","date":"2021","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35185295","citation_count":4,"is_preprint":false},{"pmid":"37599524","id":"PMC_37599524","title":"lncRNA ARAP1-AS1 enhances proliferation and impairs apoptosis of lymphoma cells by sponging miR-6867-5p.","date":"2023","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/37599524","citation_count":3,"is_preprint":false},{"pmid":"39090630","id":"PMC_39090630","title":"ARAP1-AS1: a novel long non-coding RNA with a vital regulatory role in human cancer development.","date":"2024","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/39090630","citation_count":2,"is_preprint":false},{"pmid":"39934854","id":"PMC_39934854","title":"Aberrant expression of GTPase-activating protein ARAP1 triggers circular dorsal ruffles associated with malignancy in hepatocellular carcinoma Hep3B cells.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39934854","citation_count":2,"is_preprint":false},{"pmid":"40227114","id":"PMC_40227114","title":"ARAP1-AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR-508-5p to Activate the EMP1-PI3K/AKT Pathway.","date":"2025","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40227114","citation_count":1,"is_preprint":false},{"pmid":"38260345","id":"PMC_38260345","title":"GTPase-activating protein ARAP1 regulates circular dorsal ruffles as a nutrient uptake mechanism in the Hep3B hepatocellular carcinoma cell line.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38260345","citation_count":0,"is_preprint":false},{"pmid":"41036138","id":"PMC_41036138","title":"Association of MIF rs1007888 and ARAP1 rs1552224 genetic variants with the risk of gestational diabetes mellitus in a chinese population; case study and meta-analysis.","date":"2025","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41036138","citation_count":0,"is_preprint":false},{"pmid":"41488654","id":"PMC_41488654","title":"ARAP1 fine-tunes F-actin polymerization level in lymphocytes through RhoA inhibition.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41488654","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24796,"output_tokens":5138,"usd":0.075729},"stage2":{"model":"claude-opus-4-6","input_tokens":8633,"output_tokens":4601,"usd":0.237285},"total_usd":0.313014,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"ARAP1 has PIP3-dependent Arf GAP activity and Rho GAP activity in vitro; it associates with the Golgi; Rho GAP activity mediates cell rounding and loss of stress fibers; Arf GAP activity mediates Golgi changes and filopodia formation via increased Cdc42 activity; both activities contribute to inhibiting cell spreading.\",\n      \"method\": \"In vitro GAP assays, overexpression with functional readouts (cell rounding, stress fibers, filopodia), Golgi localization by imaging\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assays plus multiple cellular functional readouts in a foundational, highly-cited paper\",\n      \"pmids\": [\"11804590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ARAP1 (493-aa isoform identified by yeast two-hybrid) binds the C-terminal region of the angiotensin II type 1A receptor (AT1A) and promotes recycling of internalized AT1A to the plasma membrane in HEK-293 cells, co-localizing with recycled AT1A at the membrane 45 min after Ang II treatment.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, immunocytochemistry, functional Ca2+ release assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal Co-IP plus co-localization and functional assay, single lab\",\n      \"pmids\": [\"14559250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARAP1 is recruited transiently to Rab5-positive, EEA1-negative early endocytic puncta containing EGFR upon EGF stimulation; knockdown of ARAP1 accelerates EGF association with EEA1 endosomes and EGFR degradation, and reduces duration of ERK and JNK phosphorylation, indicating ARAP1 controls an early endocytic checkpoint to delay EGFR signal attenuation.\",\n      \"method\": \"siRNA knockdown, live/fixed imaging with Rab5/EEA1/rabaptin-5 markers, EGFR degradation assay, ERK/JNK phosphorylation time course\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined cellular phenotype plus multiple orthogonal readouts, replicated by independent lab (PMID 18764928)\",\n      \"pmids\": [\"18939958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARAP1 localizes to Golgi and endosomal compartments, enriched in internal membranes of multivesicular bodies; its distribution is controlled by phosphorylation and by binding to 3- and 4-phosphorylated phosphoinositides through its PH domains; ARAP1 knockdown causes EGFR accumulation in sorting/late endosomes and inhibits EGFR degradation with prolonged downstream signaling.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence, siRNA knockdown, EGFR trafficking/degradation assay, phosphorylation analysis\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, independent replication of ARAP1 endosomal function (consistent with PMID 18939958)\",\n      \"pmids\": [\"18764928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The first PH domain (PH1) of ARAP1 specifically binds PtdIns(3,4,5)P3 with ~1.6 µM affinity; this binding allosterically stimulates Arf GAP catalytic activity without mediating membrane recruitment; PtdIns(3,4,5)P3 binding to PH1 is required for ARAP1 function as a regulator of EGFR endocytic trafficking in cells.\",\n      \"method\": \"Lipid-binding assays (in vitro), in vitro GAP activity assay with PH domain mutants, membrane recruitment assay in cells, EGFR trafficking assay with PH mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis plus cellular functional validation\",\n      \"pmids\": [\"19666464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PTK6 (Brk) directly phosphorylates ARAP1 at Tyr231; this phosphorylation is EGF/EGFR-dependent and requires the SH2 domain (Arg105) of PTK6; phosphorylated ARAP1 inhibits EGFR down-regulation, whereas the Y231F mutant of ARAP1 does not, linking PTK6-mediated phosphorylation of ARAP1 to sustained EGFR signaling in breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, MALDI-TOF mass spectrometry, in vitro/cell-based phosphorylation assay, site-directed mutagenesis (Y231F), EGFR degradation assay, PTK6 siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — phosphorylation identified by mass spec, confirmed by mutagenesis, with functional rescue assay\",\n      \"pmids\": [\"20554524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ARAP1 associates with CIN85 via its PXPXXRX motif (Arg86/Arg90) interacting with CIN85 SH3 domains; this interaction is required for ARAP1-dependent routing of EGFR away from the EEA1-positive early endosome; ARAP1 overexpression reduces Cbl-mediated EGFR ubiquitination and slows Cbl-dependent EGFR degradation, and a CIN85-binding-deficient ARAP1 mutant fails to rescue EGFR trafficking.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis, siRNA knockdown (ARAP1 and CIN85), EGFR ubiquitination assay, EGFR degradation assay\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, mutagenesis, and multiple functional assays in one study\",\n      \"pmids\": [\"21275903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ARAP1 is recruited to circular dorsal ruffles (CDRs) upon growth factor stimulation and increases CDR ring size in an Arf GAP activity-dependent manner; dominant-negative Arf1 and Arf5 expand CDR size, placing Arf1 and Arf5 downstream of ARAP1 in CDR ring size control.\",\n      \"method\": \"Overexpression/knockdown with live imaging and phalloidin staining, dominant-negative Arf constructs, Arf GAP-dead ARAP1 mutants\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (dominant-negative Arfs) plus gain/loss-of-function with specific morphological readout\",\n      \"pmids\": [\"22573888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Arap1-deficient mice show reduced vascular sensitivity to angiotensin II (demonstrated in isolated perfused kidney), accelerated sepsis-induced hypotension, and increased plasma renin concentration, consistent with ARAP1 promoting AT1 receptor surface expression in vascular smooth muscle/mesangial cells in vivo.\",\n      \"method\": \"Arap1 knockout mouse, isolated perfused kidney vascular resistance assay, telemetric blood pressure, LPS endotoxemia model\",\n      \"journal\": \"Critical care (London, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse with defined physiological phenotype plus in vitro vascular assay\",\n      \"pmids\": [\"23844607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARAP1 interacts with the intracellular part of TRAIL death receptor DR4 (identified by yeast two-hybrid); ARAP1 co-precipitates with DR4 and co-localizes with it in the ER/Golgi, plasma membrane, and early endosomes; ARAP1 knockdown significantly reduces DR4 cell-surface localization in tumor cell lines and slows TRAIL-induced death.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown, flow cytometry for surface DR4, cell death assay\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple methods in single lab; functional consequence of knockdown demonstrated\",\n      \"pmids\": [\"18165900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In osteoclasts, ARAP1 is part of a podosome/sealing zone complex where its RhoGAP domain regulates actin dynamics; at endosomes, ARAP1 interacts with AP-3 adaptor complexes and its Arf-GAP domain regulates Arf1-dependent AP-3 membrane binding, controlling lysosomal membrane protein transport to ruffled borders; ARAP1 or AP-3 depletion reduces osteoclast bone-digesting capacity in vitro, and AP-3δ-deficient mocha mice develop osteoporosis.\",\n      \"method\": \"Co-immunoprecipitation, domain-specific mutants, siRNA knockdown, bone resorption assay, mouse model (mocha)\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, domain mutants, multiple functional assays, and in vivo mouse model\",\n      \"pmids\": [\"30240610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure and biochemical analysis revealed that the CIN85 SH3B domain binds the ARAP1 PXPXXRX(except P)XXR/H/K motif with high affinity and specificity; the β2-β3 loops of CIN85 SH3 domains and H87ARAP1/E132CIN85 interaction confer binding specificity; ARAP1 competes with Cbl for CIN85 binding, providing a structural basis for ARAP1-mediated attenuation of EGFR internalization.\",\n      \"method\": \"Crystal structure determination, ITC, analytical gel-filtration chromatography, mutagenesis, domain-swapping\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus ITC quantification plus mutagenesis validation\",\n      \"pmids\": [\"29589748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Arap1 knockout mice develop photoreceptor degeneration starting at 4 weeks; Arap1 is expressed in Müller glia (not photoreceptors), implicating a non-cell-autonomous role of ARAP1 in photoreceptor survival via Müller glia.\",\n      \"method\": \"Knockout mouse, OCT imaging, fundus photography, immunohistochemistry, electroretinography\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse with well-defined retinal phenotype, though mechanism unresolved\",\n      \"pmids\": [\"28324111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Conditional knockout of Arap1 in RPE (using Vmd2-Cre) but not in Müller glia (Glast-Cre) recapitulates the photoreceptor degeneration phenotype; Arap1-/- RPE shows a clear phagocytic defect in vivo; mass spectrometry of ARAP1 co-IP identified candidate binding partners involved in phagocytosis, cytoskeletal organization, and intracellular trafficking.\",\n      \"method\": \"Conditional knockout mouse (cell-type-specific Cre lines), outer-segment phagocytosis quantification in vivo, co-immunoprecipitation mass spectrometry\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific knockouts precisely localize function to RPE, phagocytosis directly quantified in vivo\",\n      \"pmids\": [\"35758026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARAP1 overexpression significantly inhibits migration and invasion of lung adenocarcinoma cells in vitro and in vivo; an Arf-GAP-dead mutant does not rescue, whereas RhoGAP activity is responsible for suppressing stress fiber formation and thereby metastasis.\",\n      \"method\": \"Overexpression with RhoGAP-dead mutant controls, stress fiber imaging, Transwell migration/invasion assay, in vivo xenograft\",\n      \"journal\": \"Discover oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — domain-specific mutant analysis plus in vivo validation, single lab\",\n      \"pmids\": [\"38008882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARAP1 modulates RhoA activity at cell protrusions via its RA domain, which binds Rap1 and Rac1; ARAP1-deficient lymphocytes show enhanced chemokine-directed migration with increased RhoA activation and F-actin polymerization; ARAP1 overexpression inhibits migration in a RhoGAP-domain-dependent manner; the RA domain binding of Rap1/Rac1 is required for ARAP1-mediated RhoA inhibition.\",\n      \"method\": \"ARAP1 knockout/overexpression, Rho biosensor imaging, F-actin measurement, RA-domain mutants, Rap1/Rac1 binding assay, chemotaxis assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including live biosensor imaging, domain-specific mutants, and defined cellular phenotype\",\n      \"pmids\": [\"41488654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The T2D-risk allele (C) of rs11603334, near an ARAP1 promoter, shows ~2-fold higher transcriptional activity in reporter assays and reduced binding of transcriptional regulators PAX6 and PAX4 in EMSA; the C allele is associated with increased ARAP1 mRNA in human pancreatic islet samples, suggesting PAX6/PAX4-mediated repression normally limits ARAP1 expression in beta cells.\",\n      \"method\": \"Luciferase reporter assay in pancreatic beta cell lines, EMSA, allele-specific mRNA quantification in human islets\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay plus EMSA plus human islet allele-specific expression, single lab\",\n      \"pmids\": [\"24439111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARAP1 maintains persistent EGFR activation in high-glucose-treated HK-2 cells by reducing EGFR ubiquitination through competing with Cbl for CIN85 binding; lncRNA ARAP1-AS2 directly interacts with ARAP1 protein (RNA pulldown), promoting this mechanism to activate TGF-β/Smad3 signaling and fibrosis.\",\n      \"method\": \"RNA pulldown, co-immunoprecipitation, ubiquitination assay, dual-immunofluorescence, EGFR signaling assay, siRNA/overexpression\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — mechanistic dissection of ARAP1/CIN85/Cbl competition confirmed by ubiquitination and Co-IP, single lab\",\n      \"pmids\": [\"32969198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Hep3B hepatocellular carcinoma cells, ARAP1 localizes to CDRs and mitochondria (not observed in control HCC lines); ARAP1 KO reduces CDR size, disrupts lamellipodia architecture, attenuates macropinocytic nutrient uptake, and reduces cell growth and invasive potential; ARAP1 is actively degraded via proteasome in Hep3B cells, explaining its lower absolute level despite pro-CDR function.\",\n      \"method\": \"ARAP1 CRISPR KO, confocal microscopy, high-resolution SEM, proteasome inhibitor (MG132), macropinocytosis assay, cell proliferation and Transwell assays\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO plus pharmacological tools plus multiple imaging modalities, single lab\",\n      \"pmids\": [\"39934854\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARAP1 is a PIP3-dependent dual GTPase-activating protein (Arf GAP and Rho GAP) that integrates phosphoinositide, Arf, and Rho signaling: its PH1 domain binds PIP3 to allosterically activate Arf GAP catalytic activity (targeting Arf1/Arf5), while its RhoGAP domain suppresses RhoA/Rho-driven actin stress fibers; at the endosomal level, ARAP1 associates with CIN85 (via a defined PXPXXR motif characterized structurally) to delay EGFR routing to EEA1-positive early endosomes and compete with Cbl for CIN85 binding, thereby reducing EGFR ubiquitination and slowing receptor degradation; PTK6 phosphorylates ARAP1-Tyr231 in an EGF-dependent manner to reinforce this pro-EGFR effect; ARAP1 also promotes AT1 receptor recycling to the plasma membrane and DR4 surface presentation, regulates CDR ring size through Arf1/5, and in the retina, ARAP1 expression in the RPE is required for outer-segment phagocytosis and photoreceptor survival; in lymphocytes, its RA domain binds Rap1/Rac1 at protrusions to spatially restrict RhoA activity and fine-tune F-actin polymerization and migration.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ARAP1 is a phosphoinositide-regulated dual GTPase-activating protein that coordinates Arf and Rho GTPase signaling to control endosomal trafficking, actin cytoskeletal remodeling, and receptor fate decisions. Its PH1 domain binds PtdIns(3,4,5)P3 with micromolar affinity to allosterically activate Arf GAP catalytic activity targeting Arf1/Arf5, while its RhoGAP domain inactivates RhoA to suppress stress fibers and regulate cell migration; an RA domain binds Rap1/Rac1 at cell protrusions to spatially restrict RhoA activity [PMID:11804590, PMID:19666464, PMID:41488654]. ARAP1 controls an early endocytic checkpoint for EGFR by associating with CIN85 via a structurally characterized PXPXXR motif, competing with Cbl for CIN85 binding to reduce EGFR ubiquitination and delay receptor degradation, a process reinforced by PTK6-mediated phosphorylation of ARAP1-Tyr231 [PMID:18939958, PMID:21275903, PMID:29589748, PMID:20554524]. In the retina, ARAP1 expression in the retinal pigment epithelium is required for outer-segment phagocytosis and photoreceptor survival, as conditional RPE-specific knockout recapitulates the photoreceptor degeneration seen in global knockouts [PMID:35758026, PMID:28324111].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"The foundational enzymatic activities of ARAP1 were established: PIP3-dependent Arf GAP and Rho GAP activities that respectively regulate Golgi morphology/filopodia and stress fiber disassembly, defining ARAP1 as a dual-specificity GAP linking phosphoinositide signaling to cytoskeletal and membrane dynamics.\",\n      \"evidence\": \"In vitro GAP assays and overexpression phenotypes (cell rounding, filopodia, Golgi changes) in cultured cells\",\n      \"pmids\": [\"11804590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous substrates (which Arf and Rho family members) not fully resolved in vivo\", \"Membrane targeting mechanism not yet defined\", \"Physiological contexts beyond overexpression not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ARAP1 was linked to GPCR recycling by demonstrating that it binds the AT1A receptor cytoplasmic tail and promotes receptor recycling to the plasma membrane, extending its functional scope beyond cytoskeletal regulation.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, co-localization, and calcium release assay in HEK-293 cells\",\n      \"pmids\": [\"14559250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Shorter 493-aa isoform used; relevance to full-length protein unclear\", \"No loss-of-function validation of receptor recycling at this stage\", \"Mechanism linking Arf GAP activity to receptor recycling not dissected\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Two independent studies converged to establish ARAP1 as a gatekeeper of early endosomal trafficking: ARAP1 is recruited to Rab5-positive/EEA1-negative compartments upon EGF stimulation, and its depletion accelerates EGFR transit to EEA1 endosomes and modulates receptor degradation kinetics and downstream MAPK signaling duration.\",\n      \"evidence\": \"siRNA knockdown with live/fixed imaging, EGFR degradation assays, ERK/JNK phosphorylation time courses, subcellular fractionation (two independent labs)\",\n      \"pmids\": [\"18939958\", \"18764928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ARAP1 recruitment to pre-EEA1 compartments undefined\", \"Which GAP activity (Arf or Rho) mediates the endosomal checkpoint not resolved\", \"Role of PH domain–PIP3 interaction in endosomal function not yet tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"ARAP1 was shown to interact with death receptor DR4 and promote its surface presentation, linking ARAP1 trafficking function to TRAIL-mediated apoptosis.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, co-localization, siRNA knockdown with surface DR4 quantification and cell death assay in tumor cell lines\",\n      \"pmids\": [\"18165900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo validation\", \"Mechanism by which ARAP1 promotes DR4 surface localization not defined\", \"Whether Arf GAP or Rho GAP activity is involved not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The allosteric activation mechanism was defined: PH1-domain binding of PtdIns(3,4,5)P3 (~1.6 µM Kd) stimulates Arf GAP catalytic activity without being required for membrane recruitment, establishing the molecular logic by which PI3K signaling controls ARAP1 enzymatic output.\",\n      \"evidence\": \"In vitro lipid-binding and GAP assays with PH domain mutants, cellular EGFR trafficking rescue experiments\",\n      \"pmids\": [\"19666464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of allosteric activation not determined\", \"How PH1 mutants affect Rho GAP activity not tested\", \"Relative contributions of PIP3-dependent versus PIP3-independent activity in vivo unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"PTK6-mediated phosphorylation of ARAP1-Tyr231 was identified as an EGF-dependent post-translational switch that reinforces ARAP1's ability to inhibit EGFR degradation, connecting receptor tyrosine kinase signaling to ARAP1 regulation.\",\n      \"evidence\": \"Mass spectrometry identification of pY231, mutagenesis (Y231F), PTK6 knockdown, EGFR degradation assays in breast cancer cells\",\n      \"pmids\": [\"20554524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream consequence of pY231 on GAP activity or protein interactions not resolved\", \"Whether other kinases phosphorylate Y231 not tested\", \"Relevance outside breast cancer cells not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The molecular mechanism of ARAP1's endosomal checkpoint was clarified: ARAP1 binds CIN85 SH3 domains via a PXPXXR motif, competes with Cbl for CIN85 binding, reduces EGFR ubiquitination, and a CIN85-binding-deficient mutant fails to regulate EGFR trafficking.\",\n      \"evidence\": \"Co-IP, mutagenesis (Arg86/Arg90), siRNA of ARAP1 and CIN85, EGFR ubiquitination and degradation assays\",\n      \"pmids\": [\"21275903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of ARAP1–CIN85–Cbl competition in endogenous complexes unknown\", \"Whether Arf GAP activity is required in addition to CIN85 binding for the checkpoint not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"ARAP1 was placed upstream of Arf1 and Arf5 in circular dorsal ruffle morphogenesis: ARAP1 increases CDR ring size in an Arf GAP-dependent manner, and dominant-negative Arf1/5 phenocopy ARAP1 overexpression.\",\n      \"evidence\": \"Overexpression and knockdown with live imaging, Arf GAP-dead mutants, dominant-negative Arf constructs\",\n      \"pmids\": [\"22573888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDR size regulation affects macropinocytosis not addressed at this stage\", \"Mechanism linking Arf inactivation to CDR expansion not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"In vivo physiological relevance was demonstrated: Arap1-knockout mice show reduced vascular sensitivity to angiotensin II and accelerated sepsis-induced hypotension, validating ARAP1's role in AT1 receptor recycling and vascular tone regulation.\",\n      \"evidence\": \"Arap1 knockout mouse, isolated perfused kidney, telemetric blood pressure, LPS endotoxemia model\",\n      \"pmids\": [\"23844607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contribution (smooth muscle vs. endothelium) not resolved\", \"Whether the vascular phenotype involves Arf GAP, Rho GAP, or both activities not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A type 2 diabetes risk allele (rs11603334 C) was linked to increased ARAP1 transcription in pancreatic islets via reduced PAX6/PAX4 repressor binding, implicating ARAP1 expression levels in beta-cell biology.\",\n      \"evidence\": \"Luciferase reporter assay, EMSA, allele-specific mRNA quantification in human islets\",\n      \"pmids\": [\"24439111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of increased ARAP1 in beta cells not established\", \"No beta-cell-specific knockout or gain-of-function study performed\", \"Causality between ARAP1 levels and diabetes risk not demonstrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Arap1 knockout mice develop photoreceptor degeneration from 4 weeks of age, with ARAP1 expressed in Müller glia, initially suggesting a non-cell-autonomous support mechanism for photoreceptor survival.\",\n      \"evidence\": \"Knockout mouse with OCT, fundus imaging, immunohistochemistry, ERG\",\n      \"pmids\": [\"28324111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type responsible for the phenotype not definitively assigned\", \"Mechanism of photoreceptor degeneration unknown\", \"Müller glia attribution later revised by conditional knockout data\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Two studies expanded ARAP1's functional scope: structurally, the CIN85 SH3B–ARAP1 PXPXXR interaction was resolved by crystallography, explaining specificity and competition with Cbl; functionally, ARAP1 was shown to regulate osteoclast bone resorption via RhoGAP-dependent podosome dynamics and ArfGAP-dependent AP-3-mediated lysosomal transport to ruffled borders.\",\n      \"evidence\": \"Crystal structure, ITC, mutagenesis for CIN85 binding; co-IP, domain mutants, siRNA, bone resorption assay, mocha mouse model for osteoclast function\",\n      \"pmids\": [\"29589748\", \"30240610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ARAP1-AP-3 interaction is regulated at endosomes not defined\", \"Whether CIN85 structural insights apply to osteoclast trafficking not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The ARAP1–CIN85–Cbl competition mechanism was validated in diabetic nephropathy models, where lncRNA ARAP1-AS2 binds ARAP1 protein to sustain EGFR activation and drive TGF-β/Smad3 fibrotic signaling under high glucose.\",\n      \"evidence\": \"RNA pulldown, co-IP, ubiquitination assay, EGFR signaling in HK-2 cells under high glucose\",\n      \"pmids\": [\"32969198\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ARAP1-AS2 binding modulates ARAP1 protein function mechanistically is unclear\", \"In vivo relevance in diabetic kidney not shown\", \"Generalizability beyond HK-2 cell line not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cell-type-specific conditional knockouts definitively assigned the retinal phenotype to RPE (not Müller glia): RPE-specific Arap1 deletion recapitulates photoreceptor degeneration with a clear phagocytic defect, revising the earlier Müller glia hypothesis.\",\n      \"evidence\": \"Conditional knockout (Vmd2-Cre for RPE, Glast-Cre for Müller glia), in vivo phagocytosis quantification, co-IP mass spectrometry\",\n      \"pmids\": [\"35758026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phagocytic step requiring ARAP1 (recognition, engulfment, digestion) not defined\", \"Which GAP activity mediates RPE phagocytosis not tested\", \"Candidate partners from mass spectrometry not validated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ARAP1's RhoGAP activity was shown to suppress lung adenocarcinoma migration and invasion by eliminating stress fibers, with an Arf-GAP-dead mutant retaining anti-metastatic function, demonstrating domain-specific contributions to cancer cell motility.\",\n      \"evidence\": \"Overexpression with domain-specific mutants, Transwell assays, in vivo xenograft\",\n      \"pmids\": [\"38008882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous ARAP1 expression/loss-of-function in lung adenocarcinoma not tested\", \"Whether RhoGAP activity alone suffices in other cancer contexts unknown\", \"Downstream RhoA effectors mediating anti-metastatic effect not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"ARAP1's RA domain was shown to bind Rap1 and Rac1 at lymphocyte protrusions, spatially restricting RhoA activity; ARAP1-deficient lymphocytes exhibit enhanced migration with increased RhoA and F-actin, establishing a Rap1/Rac1→ARAP1→RhoA signaling axis in immune cell motility.\",\n      \"evidence\": \"Knockout and overexpression, Rho biosensor live imaging, RA-domain mutants, chemotaxis assay in lymphocytes\",\n      \"pmids\": [\"41488654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RA domain binding activates RhoGAP catalysis mechanistically unknown\", \"In vivo immune phenotype of ARAP1-deficient lymphocytes not characterized\", \"Whether Rap1 and Rac1 act redundantly or sequentially not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"In hepatocellular carcinoma cells, ARAP1 was shown to localize to CDRs and mitochondria, with ARAP1 knockout reducing CDR size, macropinocytic nutrient uptake, and cell growth; ARAP1 is actively degraded via the proteasome in these cells.\",\n      \"evidence\": \"CRISPR KO, confocal and SEM imaging, macropinocytosis assay, MG132 treatment in Hep3B cells\",\n      \"pmids\": [\"39934854\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mitochondrial localization not validated by independent methods or in other cell types\", \"Whether macropinocytosis effect is Arf GAP-dependent not tested\", \"Mechanism of proteasomal targeting not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for PIP3-mediated allosteric activation of ARAP1's Arf GAP domain, the specific phagocytic substep requiring ARAP1 in RPE, and how the RA domain mechanistically couples Rap1/Rac1 binding to RhoGAP catalytic activation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length ARAP1 structure available\", \"No reconstituted phagocytosis assay with defined ARAP1 mutants in RPE\", \"Inter-domain allosteric communication not characterized biochemically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 7, 15]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 7, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 3, 9]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [2, 3, 10]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [7, 10, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 5, 15]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [2, 3, 6, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CIN85\",\n      \"EGFR\",\n      \"AGTR1\",\n      \"TNFRSF10A\",\n      \"PTK6\",\n      \"AP3D1\",\n      \"RAP1A\",\n      \"RAC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}